U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
Source link
Trending
- Despite geopolitical crisis, India’s economic fundamentals and strategic partnerships will sustain growth: World Bank
- All 24 Indian crew rescued from tanker set ablaze off Oman after US strike
- ‘They are isolated … they are alone’: Zelenskyy on Russia, Putin’s lies – and fighting back | Volodymyr Zelenskyy
- ‘Could have been murdered by contract killers if …’: Ex-TMC MP Sukhendu Sekhar Ray’s big claim after quitting Mamata’s party | India News
- IIT Jammu launch new interdisciplinary programmes for 2026-27
- Freedom 250: “We’re expecting Super Bowl-type numbers”
- PepsiCo Is Now Moving Soda And Snacks Using Driverless Box Trucks
- Scientists may have debunked one of humanity’s oldest habits
